Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an ...

Eli Lilly's drug, called eloralintide, helped some patients lose more than 11% of their body weight in three months.

Part of the appeal of amylin analogs is the potential to drive weight loss without causing the same level of tolerability problems as GLP-1 receptor agonists. Lilly reported relatively low rates of ...

In today's Pharmalittle roundup, we're reading about a Lilly deal, a gene therapy shock for Duchenne families, and more.

Eli Lilly lands an $870 million pact with Camurus to build long-acting obesity treatments, tapping FluidCrystalslow-release ...

Eli Lilly’s (NYSE:LLY) experimental obesity ... Mid-stage trials designed to test eloralintide as a single agent and in combination with LLY's blockbuster weight loss drug Zepbound are also ...

The deal, which could be worth up to $870 million overall, will give Lilly access to a delivery technology that may help ...

Chugai plans to pair its muscle-preserving drug with Eli Lilly's orforglipron, addressing muscle loss in obesity care as the ...

June 13 (Reuters) - Eli Lilly's (LLY.N), opens new tab experimental obesity drug, eloralintide ... digestion and suppresses hunger. Mid-stage trials are ongoing, both as a standalone treatment ...